Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis

Raphaela Lohaus,Jonathan Michel,Katharina Mayer,Anna Lena Lahmann,Robert A. Byrne,Annabelle Wolk,Jurriën M. ten Berg,Franz-Josef Neumann,Yaling Han,Tom Adriaenssens,Ralph Tölg,Melchior Seyfarth,Michael Maeng,Bernhard Zrenner,Claudius Jacobshagen,Jochen Wöhrle,Sebastian Kufner,Tanja Morath,Tareq Ibrahim,Isabell Bernlochner,Marcus Fischer,Heribert Schunkert,Karl-Ludwig Laugwitz,Julinda Mehilli,Adnan Kastrati,Stefanie Schulz-Schüpke

Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis

2016

Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis

Keywords:

Clopidogrel
Drug
Ticlopidine
Study Subgroup
Surgery
Acute coronary syndrome
Medicine
Stent
Myocardial infarction
Stroke
Hazard ratio
Clinical endpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations